

Lucia Lopalco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006136/publications.pdf>

Version: 2024-02-01

95
papers

4,724
citations

125106

35
h-index

116156

66
g-index

96
all docs

96
docs citations

96
times ranked

4986
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals. <i>EBioMedicine</i> , 2022, 77, 103888.	2.7	39
2	Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection. <i>Cells</i> , 2022, 11, 77.	1.8	1
3	Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve. <i>Communications Medicine</i> , 2021, 1, .	1.9	18
4	Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission. <i>Frontiers in Immunology</i> , 2021, 12, 785072.	2.2	4
5	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. <i>Molecules</i> , 2020, 25, 5888.	1.7	25
6	Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. <i>Vaccines</i> , 2020, 8, 41.	2.1	7
7	Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. <i>Frontiers in Immunology</i> , 2020, 11, 1049.	2.2	88
8	Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4869-4886.	2.4	81
9	Short Communication: Decreased Plasma Calcitonin Gene-Related Peptide as a Novel Biomarker for HIV-1 Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 52-55.	0.5	3
10	The Abrogation of Phosphorylation Plays a Relevant Role in the CCR5 Signalosome Formation with Natural Antibodies to CCR5. <i>Viruses</i> , 2018, 10, 9.	1.5	6
11	M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. <i>Scientific Reports</i> , 2017, 7, 41018.	1.6	9
12	Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity. <i>MedChemComm</i> , 2017, 8, 422-433.	3.5	5
13	The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection. <i>Frontiers in Immunology</i> , 2017, 8, 1358.	2.2	33
14	Induction of Antihuman CCR5 Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector. <i>Frontiers in Immunology</i> , 2017, 8, 1402.	2.2	2
15	GM-3 Lactone Mimetic Interacts with CD4 and HIV-1 Env Proteins, Hampering HIV-1 Infection without Inducing a Histopathological Alteration. <i>ACS Infectious Diseases</i> , 2016, 2, 564-571.	1.8	5
16	Class B β -arrestin2-dependent CCR5 signalosome retention with natural antibodies to CCR5. <i>Scientific Reports</i> , 2016, 6, 39382.	1.6	12
17	Dysfunctions in the migratory phenotype and properties of circulating immature transitional B cells during HIV-1 infection. <i>Aids</i> , 2016, 30, 2169-2177.	1.0	5
18	High-efficiency antibody discovery achieved with multiplexed microscopy. <i>Microscopy (Oxford)</i> , 2016, 2016, 1-10.	0.7	34

#	ARTICLE	IF	CITATIONS
19	ERK1-Based Pathway as a New Selective Mechanism To Modulate CCR5 with Natural Antibodies. <i>Journal of Immunology</i> , 2015, 195, 3045-3057.	0.4	12
20	Tackling HIV: Genetic vs. Immune CCR5 targeting. <i>Journal of AIDS & Clinical Research</i> , 2014, 05, .	0.5	1
21	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. <i>Journal of Translational Medicine</i> , 2014, 12, 335.	1.8	13
22	Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. <i>Journal of Translational Medicine</i> , 2014, 12, 346.	1.8	14
23	Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART. <i>Retrovirology</i> , 2014, 11, 76.	0.9	32
24	Induction of HIV-Blocking Anti-CCR5 IgA in Peyer's Patches without Histopathological Alterations. <i>Journal of Virology</i> , 2014, 88, 3623-3635.	1.5	12
25	Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. <i>Retrovirology</i> , 2013, 10, 71.	0.9	30
26	Calcitonin gene-related peptide inhibits Langerhans cell-mediated HIV-1 transmission. <i>Journal of Experimental Medicine</i> , 2013, 210, 2161-2170.	4.2	25
27	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. <i>PLoS ONE</i> , 2013, 8, e55438.	1.1	69
28	A Nonparametric Procedure for Defining a New Humoral Immunologic Profile in a Pilot Study on HIV Infected Patients. <i>PLoS ONE</i> , 2013, 8, e58768.	1.1	9
29	Passively Transmitted gp41 Antibodies in Babies Born from HIV-1 Subtype C-Seropositive Women: Correlation between Fine Specificity and Protection. <i>Journal of Virology</i> , 2012, 86, 4129-4138.	1.5	32
30	Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12680-12685.	3.3	115
31	Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. <i>Blood</i> , 2012, 119, 6259-6267.	0.6	83
32	Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. <i>Virology</i> , 2012, 431, 1-11.	1.1	32
33	Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. <i>Vaccine</i> , 2011, 29, 4903-4912.	1.7	38
34	Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. <i>PLoS ONE</i> , 2011, 6, e22081.	1.1	6
35	Natural anti-CCR5 antibodies in HIV-infection and -exposure. <i>Journal of Translational Medicine</i> , 2011, 9, S4.	1.8	15
36	Modeling and Spectroscopic Studies of Synthetic Diazabicyclo Analogs of the HIV-1 Inhibitor BMS-78806 and Evaluation of Their Antiviral Activity. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 287-294.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. <i>Immunity</i> , 2011, 34, 269-280.	6.6	276
38	Scarcity or Absence of Humoral Immune Responses in the Plasma and Cervicovaginal Lavage Fluids of Heavily HIV-1-Exposed But Persistently Seronegative Women. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 469-486.	0.5	46
39	Protecting the initial site of viral entry: an alternative HIV vaccine target. <i>Expert Review of Vaccines</i> , 2011, 10, 1253-1256.	2.0	7
40	Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. <i>Aids</i> , 2010, 24, 35-43.	1.0	23
41	The role of IL-1 β in reduced IL-7 production by stromal and epithelial cells: a model for impaired T cell numbers in the gut during HIV-1 infection. <i>Journal of Internal Medicine</i> , 2010, 268, 181-193.	2.7	15
42	Setting of Methods for Analysis of Mucosal Antibodies in Seminal and Vaginal Fluids of HIV Seropositive Subjects from Cambodian and Italian Cohorts. <i>PLoS ONE</i> , 2010, 5, e9920.	1.1	13
43	HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes. <i>Journal of General Virology</i> , 2010, 91, 235-241.	1.3	5
44	CCR5: From Natural Resistance to a New Anti-HIV Strategy. <i>Viruses</i> , 2010, 2, 574-600.	1.5	108
45	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. <i>Journal of Translational Medicine</i> , 2009, 7, 101.	1.8	5
46	HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis. <i>Mucosal Immunology</i> , 2009, 2, 412-426.	2.7	140
47	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	6.0	2
48	Abundant and Superficial Expression of C-Type Lectin Receptors in Ectocervix of Women at Risk of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 239-247.	0.9	33
49	The "immunologic advantage"™ of HIV-exposed seronegative individuals. <i>Aids</i> , 2009, 23, 161-175.	1.0	106
50	Two Amino Acid Substitutions within the First External Loop of CCR5 Induce Human Immunodeficiency Virus-Blocking Antibodies in Mice and Chickens. <i>Journal of Virology</i> , 2008, 82, 4125-4134.	1.5	19
51	HIV-1 and the self-nonsel connection: how to sleep with the enemy and be much better off. <i>AIDS Reviews</i> , 2008, 10, 162-71.	0.5	4
52	Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. <i>Aids</i> , 2007, 21, 13-22.	1.0	36
53	Apolipoprotein B mRNA "Editing Enzyme, Catalytic Polypeptide" Like 3G: A Possible Role in the Resistance to HIV of HIV-Exposed Seronegative Individuals. <i>Journal of Infectious Diseases</i> , 2007, 195, 960-964.	1.9	87
54	Immunological Profile of Heterosexual Highly HIV-Exposed Uninfected Individuals: Predominant Role of CD4 and CD8 T Cell Activation. <i>Journal of Infectious Diseases</i> , 2007, 196, 1191-1201.	1.9	46

#	ARTICLE	IF	CITATIONS
55	Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. <i>Aids</i> , 2007, 21, 1048-1050.	1.0	12
56	Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. <i>Immunology</i> , 2007, 123, 070720050330001-???	2.0	26
57	Title is missing!. <i>Retrovirology</i> , 2006, 3, P36.	0.9	2
58	Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. <i>Blood</i> , 2006, 107, 4825-4833.	0.6	66
59	Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. <i>Blood</i> , 2006, 108, 1580-1587.	0.6	255
60	HIV-Specific Antibodies But Not T-Cell Responses Are Associated With Protection in Seronegative Partners of HIV-1-Infected Individuals in Cambodia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 412-419.	0.9	38
61	Upregulation of Interferon-?? and RANTES in the Cervix of HIV-1-Seronegative Women With High-Risk Behavior. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 137-143.	0.9	40
62	Is Autoimmunity a Component of Natural Immunity to HIV?. <i>Current HIV Research</i> , 2006, 4, 177-190.	0.2	23
63	Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy. <i>Journal of Virology</i> , 2005, 79, 6848-6858.	1.5	30
64	Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. <i>Journal of General Virology</i> , 2005, 86, 339-348.	1.3	42
65	Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. <i>Aids</i> , 2005, 19, 1947-1955.	1.0	132
66	Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?. <i>Current HIV Research</i> , 2004, 2, 127-139.	0.2	24
67	CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. <i>Blood</i> , 2004, 104, 2205-2206.	0.6	37
68	Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. <i>Aids</i> , 2003, 17, 531-539.	1.0	80
69	A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions. <i>Aids</i> , 2003, 17, 43-51.	1.0	45
70	Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. <i>HIV Clinical Trials</i> , 2002, 3, 115-124.	2.0	30
71	Cross-Clade HIV-1â€™Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1â€™Exposed, Persistently Seronegative Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 413-420.	0.9	118
72	Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals. <i>Aids</i> , 2002, 16, 1003-1008.	1.0	26

#	ARTICLE	IF	CITATIONS
73	Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the $\hat{1}\pm$ -helix of gp41. <i>Aids</i> , 2002, 16, 1731-1741.	1.0	75
74	Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. <i>Aids</i> , 2001, 15, 431-432.	1.0	95
75	Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. <i>Aids</i> , 2000, 14, 1917-1920.	1.0	174
76	Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. <i>Aids</i> , 2000, 14, 2083-2092.	1.0	112
77	Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells. <i>Journal of Immunology</i> , 2000, 165, 5170-5176.	0.4	239
78	CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro. <i>Journal of Immunology</i> , 2000, 164, 3426-3433.	0.4	114
79	Anti-Cell Antibodies in Exposed Seronegative Individuals with HIV Type 1-Neutralizing Activity. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 109-115.	0.5	42
80	HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2000, 14, 15-21.	0.7	23
81	Control of HIV despite the Discontinuation of Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1683-1683.	13.9	305
82	Human Immunodeficiency Virus (HIV)â€™Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIVâ€™Seropositive Persons. <i>Journal of Infectious Diseases</i> , 1999, 180, 871-875.	1.9	135
83	Role of CD4 and CCR5 Levels in the Susceptibility of Primary Macrophages to Infection by CCR5-Dependent HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 983-987.	0.5	22
84	Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1079-1085.	0.5	21
85	Human Immunodeficiency Virus Type 1 Glycoprotein 120-Specific T Lymphocytes Provide Intermolecular Help for Anti-CD4 Autoantibody Production in Exposed Uninfected Subjects. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 1461-1469.	0.5	14
86	Studies on propylamine transfer activity in anti-AdoDATO antibodies. <i>Amino Acids</i> , 1997, 12, 299-308.	1.2	1
87	HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. <i>Immunology Letters</i> , 1996, 51, 39-43.	1.1	28
88	Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 273-280.	0.5	29
89	Human Antibodies to Immunodominant C5 Region of HIV-1 gp120 Cross-React with HLA Class I on Activated Cells. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 157-162.	0.5	34
90	Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class $\hat{1}\pm$ peptide-binding domain. <i>European Journal of Immunology</i> , 1993, 23, 2016-2021.	1.6	62

#	ARTICLE	IF	CITATIONS
91	Cross-Reactive Response to Human Immunodeficiency Virus Type 1 (HIV-1) gp120 and HLA Class I Heavy Chains Induced by Receipt of HIV-1-Derived Envelope Vaccines. <i>Journal of Infectious Diseases</i> , 1993, 168, 1396-1403.	1.9	30
92	Identification of Human Immunodeficiency Virus Type 1 Glycoprotein gp120/gp41 Interacting Sites by the Idiotypic Mimicry of Two Monoclonal Antibodies. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 33-39.	0.5	36
93	Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1993, 6, 1114-9.	1.0	3
94	Conserved Structural Features in the Interaction Between Retroviral Surface and Transmembrane Glycoproteins?. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1571-1580.	0.5	105
95	Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains.. <i>Journal of Experimental Medicine</i> , 1991, 174, 53-62.	4.2	109